NewAmsterdam Pharma Holding B.V. and Frazier Lifesciences Acquisition today announced that they have entered into a definitive business combination agreement at an enterpirse value of $326 million. The announcement follows reporting last week that a deal was imminent.
If approved, NewAmsterdam Pharma would list on the Nasdaq under the ticker symbol NAMS. New Amsterdam is a late clinical-stage company focused on the research and development of transformative oral therapies for major cardiometabolic diseases.
Current company shareholders are converting 100% of their existing equity interests into ordinary shares of NewAmsterdam. In addition to the funds held in the SPAC’s trust following any redemptions, an additional group of healthcare investors has committed to participate in an oversubscribed and upsized PIPE of approximately $235 million at $10.00 per share.
Frazier raised $138 million in a December 2020 IPO. Read more.
